Nav: Home

New network launched to address diabetes complications

March 31, 2016

TORONTO, ON - A new national research network was launched today to transform the health outcomes of individuals with diabetes and its related complications. It will be led by two of Canada's top researchers in the field and includes researchers conducting leading-edge health and biomedical research at nine institutions across the country.

"Diabetes is a huge burden to our health system right now. One in four Canadians have diabetes or pre-diabetes and it's costing us $16-billion per year to treat. By 2020, we anticipate that more than 3 million Canadians will have diabetes. We have an opportunity to harness the tremendous research being done in Canada to find better solutions," said Professor Gary Lewis, Director of the Banting & Best Diabetes Centre at the University of Toronto and a Senior Scientist with the University Health Network.

Lewis will lead the new Strategy for Patient-Oriented Research (SPOR) Network in Diabetes and Related Complications - with Professor Jean-Pierre Després, Scientific Director of the Cardiology Division of the Quebec Heart and Lung institute, Director of Science and Innovation at Alliance santé Québec and a Professor of Kinesiology at Université Laval.

Today, Federal Health Minister Jane Philpott announced funding from the Canadian Institutes for Health Research (CIHR) for five SPOR Networks in Chronic Disease. "These networks will produce the innovations that improve health of Canadians and position Canada as a global leader in research on these chronic diseases," said CIHR President Dr. Alain Beaudet.

Each SPOR Network will receive $12.45-million from CIHR to be matched by partners. The SPOR Network in Diabetes and Related Complications has partnered with the Canadian Diabetes Association, JDRF, the Michael Smith Foundation for Health Research, Research Manitoba, Alliance santé Quebec, New Brunswick Health Research Foundation, as well as private sector contributors including Merck Canada Inc., Astra-Zeneca Inc., Caprion Proteome Inc., and WinSanTor Inc., for a total five-year investment of an additional $19-million for the SPOR Network in Diabetes and Related Complications.

"JDRF is proud to be a SPOR partner, as we greatly value Canadian researchers working collaboratively to accelerate diabetes research. This gives patients hope for a better world, a world without type 1 diabetes (T1D) and this research will move us there faster," said Dave Prowten, President and CEO of JDRF Canada.

"Our network will facilitate meaningful connections between primary healthcare providers, their patients and relevant specialists to achieve improved care and significant cost savings within our health system," said Després.

"I have been living with T1D for 49 years, and have experienced how devastating diabetic related complications can be; I lost my eyesight 25 years ago. Last week my 14-year-old nephew was diagnosed with T1D. This disease continues its devastating path, which is what compels me to fight back and be a member of this SPOR Network," said patient advocate Debbie Sissmore. "I am delighted to represent and advocate for the Canadians that need help in the prevention and treatment of diabetes related complications."

A focus for the network will be the impact diabetes has on vulnerable groups, including Indigenous peoples, immigrants, women and lower socio-economic groups. "We know that diabetes has a disproportionate impact on these groups, but there is still much more research to be done on why and how to deliver appropriate and culturally sensitive treatments," said Lewis.

The network will be based in Toronto at the University Health Network and University of Toronto. The other partner organizations are Université de Sherbrooke, Université Laval, Université de Montréal, University of Alberta, University of British Columbia, University of Manitoba, and the University of New Brunswick.

You can learn more about the SPOR Network in Diabetes by visiting their website: http://www.SPORNetworkDiabetes.ca
-end-
For more information:

Liam Mitchell
Associate Director, Communications
Faculty of Medicine, University of Toronto
Tel: 416-978-4672
Email: liam.mitchell@utoronto.ca

University of Toronto

Related Diabetes Articles:

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.